<p>Maxim Group 的分析师 Naz Rahman 重申了对 Vivani Medical 的买入评级，维持目标价为 4.00 美元。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 透露了哪些见解。</li>
</ul>
<p>Naz Rahman 给予买入评级是基于多种因素，这些因素突显了 Vivani Medical 的良好前景。该公司正在推进其 NPM-139 塞马鲁肽植入物，提供独特的六个月给药周期，可能解决与更频繁给药方案相关的患者依从性问题。考虑到塞马鲁肽在 Ozempic 和 Wegovy 等产品中已建立的疗效和安全性，这一创新可能会捕捉到显著的市场机会。</p>
<p>此外，辉瑞最近收购 Metsera 强调了对差异化、长期肥胖治疗的高度重视。这笔交易涉及激烈的竞标战，表明主要制药公司对这类资产的强烈兴趣，这对 Vivani 的战略是个好兆头。Vivani 拥有足够的财务资源来支持其运营和临床试验，处于利用其创新方法的良好位置，进一步增强了 Naz Rahman 对买入推荐的信心。</p>
<p>VIVANI 的股价在过去六个月中也有所变化，从 1.050 美元上涨至 1.355 美元，涨幅为 29.05%。</p>

VANI

<p>分析师 Naz Rahman 来自 Maxim Group 重申了对 Vivani Medical 的买入评级，维持 4.00 美元的目标价。该推荐基于 Vivani 创新的 NPM-139 赛美特肽植入物，提供独特的六个月给药周期，可能提高患者的依从性。辉瑞最近收购 Metsera 突显了长期肥胖治疗的价值，支持了 Vivani 的战略。Vivani 的股价在六个月内上涨了 29.05%，进一步巩固了买入推荐</p>

<p>Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vivani Medical, retaining the price target of $4.00.</p>
<div class="lb-trans"><p>Maxim Group 的分析师 Naz Rahman 重申了对 Vivani Medical 的买入评级，维持目标价为 4.00 美元。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 透露了哪些见解。</li>
</ul>
</div><p>Naz Rahman has given his Buy rating due to a combination of factors that highlight Vivani Medical’s promising prospects. The company is advancing its NPM-139 semaglutide implant, which offers a unique six-month administration cycle, potentially addressing patient compliance issues associated with more frequent dosing schedules. This innovation could capture a significant market opportunity, given the well-established efficacy and safety profile of semaglutide, known from products like Ozempic and Wegovy.</p>
<div class="lb-trans"><p>Naz Rahman 给予买入评级是基于多种因素，这些因素突显了 Vivani Medical 的良好前景。该公司正在推进其 NPM-139 塞马鲁肽植入物，提供独特的六个月给药周期，可能解决与更频繁给药方案相关的患者依从性问题。考虑到塞马鲁肽在 Ozempic 和 Wegovy 等产品中已建立的疗效和安全性，这一创新可能会捕捉到显著的市场机会。</p>
</div><p>Additionally, the recent acquisition of Metsera by Pfizer underscores the high value placed on differentiated, long-duration obesity treatments. This transaction, involving a substantial bidding war, suggests strong interest from major pharmaceutical companies in such assets, which bodes well for Vivani’s strategy. With sufficient financial resources to support its operations and clinical trials, Vivani is well-positioned to capitalize on its innovative approach, reinforcing Naz Rahman’s confidence in a Buy recommendation.</p>
<div class="lb-trans"><p>此外，辉瑞最近收购 Metsera 强调了对差异化、长期肥胖治疗的高度重视。这笔交易涉及激烈的竞标战，表明主要制药公司对这类资产的强烈兴趣，这对 Vivani 的战略是个好兆头。Vivani 拥有足够的财务资源来支持其运营和临床试验，处于利用其创新方法的良好位置，进一步增强了 Naz Rahman 对买入推荐的信心。</p>
</div><p>VANI’s price has also changed moderately for the past six months – from $1.050 to $1.355, which is a 29.05% increase.</p>
<div class="lb-trans"><p>VIVANI 的股价在过去六个月中也有所变化，从 1.050 美元上涨至 1.355 美元，涨幅为 29.05%。</p>
</div>

Vivani Medical 的创新 Semaglutide 植入物及其市场定位推动了买入推荐